REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 189 filers reported holding REATA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 2.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $13,493,692 | +46.0% | 132,343 | +30.2% | 0.00% | +50.0% |
| Q1 2023 | $9,244,291 | +138.7% | 101,675 | -0.3% | 0.00% | +100.0% |
| Q4 2022 | $3,873,157 | +55.1% | 101,952 | +2.6% | 0.00% | 0.0% |
| Q3 2022 | $2,498,000 | -11.0% | 99,379 | +7.7% | 0.00% | 0.0% |
| Q2 2022 | $2,806,000 | -29.0% | 92,308 | -23.5% | 0.00% | 0.0% |
| Q1 2022 | $3,953,000 | +26.3% | 120,675 | +1.6% | 0.00% | 0.0% |
| Q4 2021 | $3,131,000 | -75.1% | 118,748 | -5.1% | 0.00% | -50.0% |
| Q3 2021 | $12,593,000 | -25.3% | 125,168 | +5.0% | 0.00% | -33.3% |
| Q2 2021 | $16,866,000 | +77.9% | 119,169 | +25.3% | 0.00% | +50.0% |
| Q1 2021 | $9,481,000 | -20.4% | 95,090 | -1.3% | 0.00% | -33.3% |
| Q4 2020 | $11,915,000 | +30.7% | 96,386 | +3.0% | 0.00% | +50.0% |
| Q3 2020 | $9,116,000 | -40.6% | 93,580 | -4.8% | 0.00% | -50.0% |
| Q2 2020 | $15,335,000 | -10.6% | 98,288 | -17.3% | 0.00% | -33.3% |
| Q1 2020 | $17,149,000 | -32.2% | 118,814 | -3.9% | 0.01% | -14.3% |
| Q4 2019 | $25,285,000 | +197.6% | 123,682 | +16.9% | 0.01% | +250.0% |
| Q3 2019 | $8,495,000 | -20.7% | 105,804 | -6.8% | 0.00% | -33.3% |
| Q2 2019 | $10,712,000 | +20.8% | 113,539 | +9.4% | 0.00% | +50.0% |
| Q1 2019 | $8,870,000 | +75.7% | 103,784 | +15.3% | 0.00% | 0.0% |
| Q4 2018 | $5,049,000 | -34.9% | 90,002 | -5.1% | 0.00% | 0.0% |
| Q3 2018 | $7,758,000 | +238.2% | 94,881 | +44.7% | 0.00% | +100.0% |
| Q2 2018 | $2,294,000 | +127.8% | 65,587 | +33.5% | 0.00% | – |
| Q1 2018 | $1,007,000 | -24.6% | 49,114 | +4.1% | 0.00% | – |
| Q4 2017 | $1,336,000 | -4.0% | 47,164 | +5.5% | 0.00% | – |
| Q3 2017 | $1,391,000 | +29.5% | 44,703 | +31.6% | 0.00% | – |
| Q2 2017 | $1,074,000 | +113.5% | 33,959 | +52.9% | 0.00% | – |
| Q1 2017 | $503,000 | +22.4% | 22,213 | +18.1% | 0.00% | – |
| Q4 2016 | $411,000 | +0.2% | 18,806 | +20.8% | 0.00% | – |
| Q3 2016 | $410,000 | +88.9% | 15,570 | +41.9% | 0.00% | – |
| Q2 2016 | $217,000 | – | 10,971 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |